|
T2239L |
Raltegravir
|
MK-0518 |
HIV Protease
,
Integrase
|
|
Raltegravir (MK-0518) is a pyrrolidinone derivative and HIV INTEGRASE INHIBITOR that is used in combination with other ANTI-HIV AGENTS for the treatment of HIV INFECTION. |
|
T2239 |
Raltegravir potassium
|
MK 0518 potassium salt,Raltegravir potassium salt |
HIV Protease
,
Integrase
|
|
Raltegravir potassium (MK 0518 potassium salt) salt(MK0518 potassium salt) is a potent integrase (IN) inhibitor, used to treat HIV infection. |
|
T62983 |
Raltegravir sodium
|
|
|
|
Raltegravir (MK 0518) sodium is a potent, orally active HIV integrase (IN) inhibitor. |
|
T2329 |
Dolutegravir sodium
|
GSK1349572,GSK-1349572A |
HIV Protease
|
|
Dolutegravir sodium (GSK-1349572A) salt(DTG; GSK1349572) is an HIV integrase inhibitor(IC50: 2.7 nM), modest activity against raltegravir-resistant signature mutants Y143R, Q148K, N155H, and G140S/Q148H. |
|
T6198 |
Dolutegravir
|
S/GSK1349572,GSK1349572 |
HIV Protease
|
|
Dolutegravir (GSK1349572) (IC50=2.7 nM), a two-metal-binding HIV integrase inhibitor, exhibits medium activity against raltegravir-resistant signature mutants Y143R, Q148K, N155H, and G140S/Q148H. |
|
T33443 |
MK-8970
|
|
|
|
MK-8970 is an acetal carbonate prodrug of raltegravir with enhanced colonic absorption. |
